This article has no abstract; the first 100 words appear below.

The development of coronary-artery stents was a major advance in interventional cardiology. However, conventional stents, which are metallic, cage-like structures, have some limitations — notably, they leave a permanent implant, which may prevent favorable arterial remodeling and preclude future surgical revascularization. Bioresorbable scaffolds were developed to overcome some of the disadvantages of metallic stents in that they gradually degrade in the body over time and leave no residual implant.1 The Absorb everolimus-eluting bioresorbable vascular scaffold (Abbott Vascular) was approved for use by the Food and Drug Administration (FDA) in July 2016.The largest trial of the Absorb bioresorbable scaffold was . . .